Abstract
Background Many of earlier studies reporting the frequency of preclinical Alzheimer’s disease (AD) among cognitive normal (CN) individuals have based on the clinical study cohort from Western countries, and it has not been validated whether the frequency of preclinical AD in Asian country cohort may differ from that in Western countries.
Methods We conducted meta-analysis of earlier literature and original data of 4 Japanese cohort study (i.e., AMED-Preclinical, Brain/Minds Aging Imaging Study, J-ADNI, and A4 study screening conducted in Japan), among which we incorporated cognitive normal (CDR = 0) clinical study participants who were examined their amyloid status by amyloid-PET or CSF.
Results In total, among the reviewed 658 Japanese CN participants from 10 different groups, 103 turned out to be amyloid positive, and the estimated overall frequency of preclinical AD (of any stage) was 17.2% (95% CI: 12.0 – 23.0%) with a high statistical heterogeneity of I2 = 64%. In meta-regression, being the Japanese cohort was barely significantly associated with the lower frequency of preclinical AD (p = 0.048).
Conclusions Our study suggested that currently there is no robust evidence to support the lower frequency of preclinical AD in clinical study settings of Japan than that of Western countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Japan Agency for Medical Research and Development grants JP17DK0207028 and JP19DK0207048, and by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Numbers 20J11009.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the University of Tokyo Graduate School of Medicine institutional ethics committee (ID: 11628-(3)).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Original data used in this study is available from NDB or LONI databases.
https://humandbs.biosciencedbc.jp/en/hum0043-v1
https://humandbs.biosciencedbc.jp/en/hum0235-v1
